We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

104 hedge funds and large institutions have $657M invested in Lexicon Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

5% more funds holding

Funds holding: 99 → 104 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

12% less capital invested

Capital invested by funds: $749M → $657M (-$92.3M)

16% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 32

Holders
104
Holders Change
+5
Holders Change %
+5.05%
% of All Funds
3.02%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
12
Increased
27
Reduced
32
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UBS AM
UBS AM
Illinois
+$6.1M
2
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Kentucky
+$778K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$186K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$167K
5
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
+$131K

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$3.87M
2
Axa
Axa
France
-$725K
3
Deutsche Bank
Deutsche Bank
Germany
-$380K
4
TA
Teton Advisors
New York
-$302K
5
Bank of America
Bank of America
North Carolina
-$260K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$523K -$20K -1,874 -3%
ProShare Advisors
27
ProShare Advisors
Maryland
$502K -$104K -9,703 -16%
TA
28
Teachers Advisors
New York
$451K – – –
DekaBank Deutsche Girozentrale
29
DekaBank Deutsche Girozentrale
Germany
$425K +$9.15K +857 +2%
RPAM
30
Rhenman & Partners Asset Management
Sweden
$416K – – –
Swiss National Bank
31
Swiss National Bank
Switzerland
$416K – – –
Stifel Financial
32
Stifel Financial
Missouri
$398K -$164K -15,367 -28%
UOTTAIMCU
33
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$353K – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$296K -$149 -14 -0%
WHI
35
William Harris Investors
Illinois
$288K – – –
MLICM
36
Metropolitan Life Insurance Company (MetLife)
New York
$266K +$131K +12,249 +83%
NFA
37
Nationwide Fund Advisors
Ohio
$250K +$2K +187 +0.7%
State Board of Administration of Florida Retirement System
38
State Board of Administration of Florida Retirement System
Florida
$228K – – –
GI
39
GAMCO Investors
Connecticut
$226K – – –
AIG
40
American International Group
New York
$213K -$171 -16 -0.1%
RTS
41
Round Table Services
New Jersey
$213K – – –
Morgan Stanley
42
Morgan Stanley
New York
$210K -$222K -20,754 -49%
Citadel Advisors
43
Citadel Advisors
Florida
$199K +$41.1K +3,853 +24%
BA
44
BlackRock Advisors
Delaware
$196K -$8.38K -785 -4%
VOYA Investment Management
45
VOYA Investment Management
Georgia
$196K – – –
CS
46
Credit Suisse
Switzerland
$187K -$131K -12,256 -39%
KFC
47
Klingenstein Fields & Co
New York
$169K – – –
TC
48
TFS Capital
Pennsylvania
$164K +$41.4K +3,880 +31%
Bank of America
49
Bank of America
North Carolina
$151K -$260K -24,375 -61%
SG Americas Securities
50
SG Americas Securities
New York
$147K +$90.6K +8,483 +133%
1
2
3 4 5

LXRX Hedge Fund Activity: Q3 2014 in Review

104 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2014, worth a combined $657M — down 12% from $749M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new LXRX positions and 7 closed out — a net gain of 5 holders — while 27 added to existing stakes and 32 trimmed.

The largest buyer was UBS AM, adding an estimated $6.1M. The largest seller was Norges Bank, cutting an estimated $3.87M.

  • 104 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2014, up from 99 in Q2 2014.
  • Funds reported $657M of Lexicon Pharmaceuticals stock for Q3 2014, down 12% quarter-over-quarter.
  • 12 funds opened new Lexicon Pharmaceuticals positions in Q3 2014 and 7 closed out, a net change of +5 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2014 was UBS AM, an estimated $6.1M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $3.87M sold.

Based on aggregated 13F filings for Q3 2014.